DexCom Inc. closed 50.22% short of its 52-week high of $142.00, which the company achieved on March 26th.

DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...

Citi raised the firm’s price target on DexCom (DXCM) to $104 from $101 and keeps a Buy rating on the shares. The firm adjusted medical ...

Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The ...

PNC Financial Services Group Inc. raised its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 21.5% in the fourth ...

DexCom's growth is slowing with 2024 marking the slowest growth year in a decade and 2025 expected to follow suit with ~14% ...

On February 14, Travis Steed, an analyst at Bank of America Securities, maintained a Buy rating while keeping his price target of $84.09. DexCom, Inc. (NASDAQ:DXCM) has been growing its customer base.

it appears that whales have been targeting a price range from $60.0 to $120.0 for DexCom over the last 3 months. Insights into Volume & Open Interest Looking at the volume and open interest is a ...

Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. DexCom is up 9.9% during the same time and is ...